



34th Board Meeting

Electronic Decision Points

2 April – 14 November 2015

GF/B34/22

Board Information

PURPOSE: This paper provides a copy of the Board's decisions that were confirmed by way of electronic vote between the end of the 33rd Board Meeting and the start of the 34th Board Meeting.

Table of electronic votes confirmed
between the end of the 33rd Board Meeting and the start of the 34th Board Meeting.
(2 April – 14 November 2015)

Reference	Title of the electronic vote	Confirmation
GF/B33/EDP01	Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation	15 May 2015
GF/B33/EDP02	Decision on the Secretariat's Recommendation on Grant Extensions	15 May 2015
GF/B33/EDP03	Appointment of Member of the Strategy, Investment and Impact Committee	4 June 2015
GF/B33/EDP04	Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation	5 June 2015
GF/B33/EDP05	Decision on the Secretariat's Recommendation on Grant Extensions	5 June 2015
GF/B33/EDP06	Appointment of a new Vice-Chair of the Finance and Operational Performance Committee	11 June 2015
GF/B33/EDP07	Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation	30 June 2015
GF/B33/EDP08	Decision on the Secretariat's Recommendation on Grant Extensions	30 June 2015
GF/B33/EDP09	Terms of Reference of the Ethics Officer	Not approved
GF/B33/EDP10	Approval of the Report of the Thirty-Third Board Meeting	7 July 2015
GF/B33/EDP11	Location of the Thirty-Fourth Board Meeting	17 July 2015
GF/B33/EDP12	Decision on the Secretariat's recommendation on Additional Funding from the 2014 Allocation	24 July 2015
GF/B33/EDP13	Decision on the Secretariat's recommendation on Grant Extensions	24 July 2015
GF/B33/EDP14	Terms of Reference of the Ethics Officer	30 July 2015

Reference	Title of the electronic vote	Confirmation
GF/B33/EDP15	Decision on the Secretariat's recommendation on Additional Funding from the 2014 Allocation)	11 September 2015
GF/B33/EDP16	Decision on the Secretariat's recommendation on Grant Extensions	11 September 2015
GF/B33/EDP17	Strategy Development Process Alignment of Strategy Cycle	Not approved
GF/B33/EDP18	Approval of the Governance Performance Assessment Framework	21 September 2015
GF/B33/EDP19	Appointment of Member of the Finance and Operational Performance Committee	8 October 2015
GF/B33/EDP20	Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation	12 October 2015
GF/B33/EDP21	Decision on the Secretariat's Recommendation on Grant Extensions	12 October 2015
GF/B33/EDP22	Decision on the Secretariat's Recommendation on waiver of the Board condition for Congo HIV grant	12 October 2015
GF/B33/EDP23	Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation	19 October 2015
GF/B33/EDP24	Decision on the Secretariat's Recommendation on Grant Extensions	19 October 2015
GF/B33/EDP25	Appointment of Member of the Strategy, Investment and Impact Committee	29 October 2015
GF/B33/EDP26	Global Fund Strategy Cycle	10 November 2015
GF/B33/EDP27	Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation	13 November 2015
GF/B33/EDP28	Decision on the Secretariat's Recommendation on Grant Extensions	13 November 2015

Reference	Title of the electronic vote	Confirmation
GF/B33/EDP29	Decision on the Secretariat's Recommendation on Policy Exceptions for Processing HIV and TB Funding Applications from Certain Countries in the Middle East Region	13 November 2015
GF/B33/EDP30	Appointment of Member of the Strategy, Investment and Impact Committee	12 November 2015

GF/B32/EDP01 Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation

Approved by the Board on 15 May 2015 by electronic vote.

The Board:

1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER01;
2. Approves the reinvestment of newly identified existing funds for the Ukraine TB/HIV program and its constituent grants and its resultant total program budget, as listed in Table 2 of Annex 1 to GF/B33/ER01;
3. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;
4. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
5. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation

N	Country	Disease Component	Proposed Principal Recipient (and Grant Name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
1	Armenia	TB	Ministry of Health of the Republic of Armenia (ARM-T-MOH)	US\$9,243,338	US\$1,310,738	US\$7,932,600	US\$7,932,600	N/A	N/A	US\$14,303,999
2	Bhutan	TB	Ministry of Health of Bhutan (BTN-T-MOH)	US\$2,088,015	US\$76,748	US\$2,011,267	US\$2,011,267	N/A	N/A	US\$2,156,202
3	Costa Rica	HIV	Humanist Institute for Cooperation (HIVOS) (CRI-H-HIVOS)	US\$4,883,405	0	US\$4,883,405	US\$4,883,405	N/A	N/A	US\$70,000,000
4	Eritrea	Malaria	Ministry of Health of Eritrea (ERI-M-MOH)	US\$29,298,779	US\$2,467,889	US\$26,830,890	US\$26,830,890	N/A	N/A	US\$3,484,599
5	Iraq	TB	UNDP (IRQ-T-UNDP)	US\$6,702,885	US\$2,202,885	US\$4,500,000	US\$4,500,000	N/A	N/A	US\$41,272,446

Table 2: Reinvestment of Efficiencies into Ukraine TB/HIV Program¹.

Grant Name	Approved Grant Budget	Revised Budget for Board Approval	Existing Funding	Revised Existing Funding	Incremental Funding Already Approved per GF/B32/EDP01	Additional Incremental Funding for Board Approval
UKR-C-AUA	US\$68,799,281	US\$70,165,850	US\$9,477,241	US\$13,374,190	US\$59,322,040*	N/A
UKR-C-AUN	US\$60,406,308	US\$66,340,308	US\$22,746,852	US\$25,273,037	US\$37,659,456	N/A
UKR-C-UCDC	US\$4,676,168	US\$4,676,168	US\$4,302,539	US\$5,583,045*	N/A	N/A
TOTAL	US\$133,881,757	US\$141,182,326	US\$36,526,632	US\$44,230,272	US\$96,981,496	N/A

*As the amount of revised existing funding for grant UKR-C-UCDC exceeds the revised budget (i.e. the funding needs) for the respective grant, the excess of US\$906,877 will be reallocated into grant UKR-C-AUN. Similarly, US\$2,530,380 of excess funding in grant UKR-C-AUA will be reallocated into grant UKR-C-AUN to finance the increased revised budget.

¹ This table summarizes reinvestment of additional savings into the Ukraine TB/HIV program. As the identified savings relate to the in-country cash balance (existing funding), the additional funding will not impact the incremental funding approved by the Board in December 2014 (GF/ B32/EDP01) but will increase existing funding and budget of constituent grants.

GF/B32/EDP02 Decision on the Secretariat's Recommendation on Grant Extensions

Approved by the Board on 15 May 2015 by electronic vote.

The Board:

1. Approves extension of the relevant implementation period for each grant listed in Table 3 of Annex 1 to GF/B33/ER01.

Table 3: Secretariat's Recommendations on Grant Extensions

Country	Grant Name	Period of Extension (Months)	Additional Funding	Rationale
Cameroon	CMR-011-G10-H	9	EUR513,172	To allow for continuation of activities while a revised concept note is being developed and discussed.
Cameroon	CMR-011-G11-H	9	EUR13,409,293	
Indonesia	IND-M-MOH	15	US\$12,252,165	To allow for continuation of grant activities while the framework agreement is being negotiated and signed.
Sudan	SUD-011-G15-H	6	N/A	To allow for continuation of activities while grant-making is being finalized and grants are approved.
Thailand	THA-H-DDC	12	US\$14,047,910	To allow for continuation of grant activities while the framework agreement is being negotiated and signed.

GF/B32/EDP03 Appointment of Member of the Strategy, Investment and Impact Committee

Approved by the Board on 4 June 2015 by electronic vote.

The Board approves the appointment of Ms. Sandra Roelofs as a voting member of the Strategy, Investment and Impact Committee (the “SIIC”) for a term that will expire on 9 March 2016, or until the appointment of her successor.

GF/B32/EDP04 Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation

Approved by the Board on 5 June 2015 by electronic vote.

The Board:

1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ERO3 ("Table 1");
2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation

N	Country	Disease Component	Proposed Principal Recipient (Grant name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
1	Bhutan	Malaria	Ministry of Health (BTN-M-MOH)	US\$1,942,261	US\$165,606	US\$1,776,655	US\$1,776,655	N/A		US\$3.3 million
2	Ethiopia	HSS	Federal Ministry of Health (ETH-S-FMOH)	US\$52,260,169	US\$7,633,004	US\$44,627,165	US\$44,627,165	N/A	US\$15,774,456	US\$19.8 million
3	Ethiopia	Malaria	Federal Ministry of Health (ETH-M-FMOH)	US\$148,752,983	US\$33,240,396	US\$115,512,587	US\$115,512,587	N/A	US\$14,154,980	US\$66.1 million
4	Gambia	HIV	NAS (GMB-H-NAS)	US\$14,768,343	US\$2,006,278	US\$9,073,538	US\$12,386,594	N/A	US\$7,843,704	US\$1,896,493
			Action Aid (GMB-H-ActionAid)		US\$375,471	US\$3,313,056				
5	Guinea	Malaria	Catholic Relief Service (GIN-M-CRS)	US\$62,200,411	US\$4,902,680	US\$57,297,731	US\$57,297,731	US\$2,078,401	N/A	US\$10,613,219
6	Lao (People Democratic Republic)	TB	Ministry of Health (LAO-T-GFMOH)	US\$7,239,191	US\$4,223,147	US\$3,016,044	US\$3,016,044	US\$1,498,395	N/A	US\$3.5 million
7	Mozambique	Malaria	Ministry of Health (MOZ-M-MOH)	US\$107,360,243	US\$41,066,178	US\$43,106,362	US\$54,224,226	US\$5,885,035	US\$93,547,916	38 million

N	Country	Disease Component	Proposed Principal Recipient (Grant name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
			World Vision (MOZ-M-WV)		US\$12,069,839	US\$11,117,864				
8	Mozambique	TB/HIV	Ministry of Health(MOZ-H-MOH)	US\$241,007,021	US\$128,925,773	US\$52,002,749	US\$ 65,398,894	US\$43,560,000	US\$231,006,779	HIV : US\$157 million TB: US\$10 million
			Ministry of Health(MOZ-T-MOH)		US\$26,329,158	US\$12,102,950				
			Fundação Para o Desenvolvimento da Comunidade (FDC)(MOZ-C-FDC)		US\$20,353,196	US\$1,293,195				
9	Papua New Guinea	HIV	Oil Search Health Foundation (PNG-H-OSHF)	US\$14,207,542	US\$6,453,334	US\$7,754,208	US\$7,754,208	N/A	N/A	US\$56.1 million
10	Philippines	HIV	Save the Children (PHL-H-SC)	US\$13,920,375	US\$1,912,042	US\$12,008,333	US\$12,008,333	US\$1,118,947	US\$2,010,341	US\$175 million
11	Sao Tome & Principe	TB	UNDP (STP-T-UNDP)	US\$1,567,681	US\$278,628	US\$1,289,053	US\$1,289,053	N/A	N/A	US\$296,000

N	Country	Disease Component	Proposed Principal Recipient (Grant name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
12	Senegal	HIV	Alliance Nationale de lutte Contre le Sida (SEN-H-ANCS)	EUR19,478,252	EUR 3,124,426	EUR 1,968,021	EUR 8,555,373	N/A	N/A	EUR 13,680,590
			Conseil National de Lutte contre le Sida (SEN-H-CNLS)		EUR 7,798,453	EUR 6,587,352				
13	Somalia	HIV	UNICEF (SOM-H-UNICEF)	US\$20,614,311	0	US\$20,614,311	US\$20,614,311	US\$1,765,506	N/A	N/A
14	Somalia	Malaria	UNICEF (SOM-M-UNICEF)	US\$33,680,843	US\$ 2,120,844	US\$31,559,999	US\$31,559,999	N/A	US\$7,651,902	N/A
15	South Sudan	TB	UNDP (SSD-T-UNDP)	US\$15,512,452	US\$3,549,802	US\$11,962,650	US\$11,962,650	US\$2,437,815	US\$4,157,812	US\$3.2 million
16	Tanzania	TB/HIV	Ministry of Finance (TZA-H-MOF)	US\$298,479,894	US\$104,745,414	US\$172,448,214	US\$190,283,793	US\$78,608,549	US\$195,254,828	HIV: US\$107 million
			Ministry of Finance (TZA-T-MOF)		US\$3,450,687	US\$17,835,579				TB: US\$6.2 million
17	Uganda	HSS	MOFPED (UGA-S-MoFPED)	US\$ 21,771,916	US\$572,761	US\$14,035,520	US\$19,920,527	N/A	US\$2,004,253	US\$214 million

N	Country	Disease Component	Proposed Principal Recipient (Grant name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
			The AIDS Support Organization (UGA-S-TASO)		US\$1,278,629	US\$5,885,007				
18	Uganda	TB/HIV	The AIDS Support Organization (UGA-C-TASO)	US\$230,505,464	US\$463,650	US\$6,341,348	US\$149,054,980	US\$19,842,776	US\$345,212,047	HIV: US\$146 million TB: US\$11.2 million
			Ministry of Finance (UGA-H-MoFPED)		US\$69,134,319	US\$131,870,252				
			Ministry of Finance (UGA-T-MoFPED)		US\$11,852,515	US\$10,843,380				
19	Viet Nam	TB/HIV	National Lung Hospital - Ministry of Health of Vietnam (VNM-H-VAAC)	US\$104,444,734	US\$56,857,168	US\$1,205,153	US\$31,122,423	N/A	US\$21,343,708	US\$123.5 million
			Vietnam Administration of HIV/AIDS Control - Ministry of Health of Vietnam (VNM-H-VUSTA)		US\$150,000	US\$6,792,775			N/A	

N	Country	Disease Component	Proposed Principal Recipient (Grant name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
			National TB Program (VNM-T-NTP)		US\$16,315,143	US\$23,124,495		US\$20,122,532	US\$18,504,761	US\$151.5 million
20	Yemen	Malaria	National Malaria Control Program (YEM-M-NMCP)	US\$19,847,283	US\$4,131,539	US\$15,715,744	US\$15,715,744	US\$1,900,000	US\$6,839,831	US\$28,325,544

GF/B32/EDP05 Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation

Approved by the Board on 5 June 2015 by electronic vote.

The Board:

1. Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER03.

Table 2: Secretariat's Recommendations on Grant Extensions

Country	Grant Name	Period of Extension (Months)	Additional Funding	Rationale
Malawi	MLW-H-NAC	6 months	US\$37,090,681	To facilitate the transition to the new funding model and to allow the initiation of the procurement order for the HIV commodities needed in Malawi for consumption during the first semester of 2016 and therefore ensure continuation of essential services while the new HIV grant is being discussed and signed.
Multi Country Americas REDCA+ HIV Grant	MAR-H-SICSA	9 months	US\$ 193,037	To allow for continuation of grant activities during the revision of concept note

GF/B32/EDP06 Appointment of a new Vice-Chair of the Finance and Operational Performance Committee:

Approved by the Board on 11 June 2015 by electronic vote.

The Board approves the appointment of Mr. Michael Ruffner as the non-voting, neutral Vice-Chair of the Finance and Operational Performance Committee (the “FOPC”) for the remainder of his predecessor’s term.

GF/B32/EDP07 Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation:

Approved by the Board on 30 June 2015 by electronic vote.

The Board:

1. Approves the incremental funding recommended for each country disease component and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER05 – Revision 1 (“Table 1”);
2. Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation

N	Country	Disease Component	Proposed Principal Recipient (Grant name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
1	Bhutan	HIV	Ministry of Health (BTN-H-MOH)	US\$2,001,227	US\$82,668	US\$1,918,559	US\$1,918,559	N/A	N/A	US\$2.5 million
2	Bulgaria	TB	Ministry of Health (BGR-T-MOH)	EUR 5,822,822	EUR 539,159	EUR 5,283,663	EUR 5,283,663	N/A	N/A	EUR 29.9 million
3	Burkina Faso	TB/HIV	Programme d'appui au développement sanitaire (BFA-T-PADS)	EUR 3,320,630	EUR 3,320,630	-	EUR 26,591,071	N/A	N/A	EUR 46 million
			National Council for the Struggle against HIV/AIDS and STI (BFA-H-SPCNLS)	EUR 28,389,051	EUR 7,760,137	EUR 20,628,914				
			Initiative Privée et Communautaire contre le VIH/SIDA (BFA-C-IPC)	EUR 6,743,006	EUR 780,849	EUR 5,962,157				

N	Country	Disease Component	Proposed Principal Recipient (Grant name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
4	Cambodia	Malaria	United Nations Office for Project Services (KHM-M-UNOPS)	US\$35,533,343	US\$27,665,658	US\$7,867,675	US\$7,867,675	N/A	N/A	US\$13 million
5	Cape Verde	Malaria	Comissão de Coordenação do Combate à Sida (CPV-M-CCSIDA)	EUR 931,251	EUR 155,497	EUR775,754	EUR775,754	N/A	N/A	EUR 1.7 million
6	Côte d'Ivoire	Malaria	Ministry of Health (CIV-M-PNLP)	EUR 72,596,079	EUR 14,903,468	EUR 57,692,611	EUR 57,692,611	EUR 29,756,332	EUR 20,107,595	EUR 65.9 million
7	Eritrea	TB	Ministry of Health (ERI-T-MOH)	US\$4,415,916	US\$4,415,916	-	-	N/A	N/A	
8	Eritrea	HIV	Ministry of Health (ERI-H-MOH)	US\$19,795,804	US\$15,994,884	US\$3,800,920	US\$3,800,920	N/A	N/A	
9	Ethiopia	TB/HIV	Federal HIV/AIDS Prevention and Control Office (ETH-H-HAPCO)	US\$276,713,816	US\$91,823,106	US\$184,890,710	US\$198,087,209	US\$10,187,974	US\$18,555,612	HIV: 59 million TB: 28 million
			Ministry of Health (ETH-T-FMOH)	US\$73,879,065	US\$60,682,566	US\$13,196,499				

N	Country	Disease Component	Proposed Principal Recipient (Grant name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
10	Fiji	TB	Ministry of Health and Medical Services (FJI-T-MHMS)	US\$4,445,477	US\$542,137	US\$3,903,340	US\$3,903,340	N/A	N/A	US\$12.2 million
11	Ghana	TB/HIV	Adventist Development and Relief Agency of Ghana grant (GHA-H-ADRA)	US\$3,300,664	US\$34,084	US\$3,266,580	US\$ 100,443,108	N/A	US\$6,375.348	US\$264.7 million
			Planned Parenthood Association of Ghana grant (GHA-H-PPAG)	US\$1,621,833	US\$84,427	US\$1,537,406				
			Ministry of Health (GHA-H-MOH)	US\$80,095,790	US\$19,156,344	US\$60,939,446				
			Ghana AIDS Commission (GHA-H-GAC)	US\$ 12,905,545	US\$289,960	US\$12,615,524.				
			Ministry of Health (GHA-T-MOH)	US\$22,506,425	US\$422,274	US\$22,084,151				

N	Country	Disease Component	Proposed Principal Recipient (Grant name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
12	Mauritius	HIV	National AIDS Secretariat (MUS-H-NAS)	US\$1,864,381	US\$391,799	US\$1,472,582	US\$1,472,582			
			Prévention Information Lutte contre le Sida (MUS-H-PILS)	US\$1,799,049	US\$55,049	US\$1,744,000	US\$1,744,000	N/A	US\$2,213,307	US\$4.7 million
13	Multicountry Western Pacific	TB/HIV	United Nations Development Programme (QMJ-C-UNDP)	US\$14,214,351	US\$3,499,759	US\$10,714,592	US\$10,714,592	N/A	N/A	N/A
14	Multicountry Western Pacific	Malaria	United Nations Development Programme (QMJ-M-UNDP)	US\$2,657,874	US\$2,657,874	-	-	N/A	N/A	N/A
15	Nicaragua	HIV	Instituto Nicaragüense de Seguridad Social (NIC-H-INSS)	US\$12,996,303	US\$3,713,235	US\$9,283,068	US\$9,283,068	N/A	N/A	US\$37.5 million

N	Country	Disease Component	Proposed Principal Recipient (Grant name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
16	Niger	HIV	Coordination Intersectorielle de Lutte contre le Sida (NER-H-CISLS)	EUR 14,259,597	EUR 4,268,833	EUR 9,990,764	EUR 9,990,764	N/A	N/A	EUR 16.6 million
17	Pakistan	TB	National TB Control Program (PAK-T-NTP)	US\$127,351,666	US\$33,894,314	US\$93,457,352	US\$102,928,266	US\$10,892,798	US\$20,205,105	US\$109.7 million
			Mercy Corps (PAK-T-MC)	US\$11,427,617	US\$1,956,703	US\$9,470,914				
18	Russian Federation	HIV	Open Health Institute Foundation (RUS-H-OHI)	US\$11,270,738	US\$401,522	US\$10,869,216	US\$10,869,216	N/A	US\$100,380,999	N/A
19	Rwanda	TB/HIV	Ministry of Health (RWA-T-MOH)	US\$21,278,134	US\$5,435,966	US\$15,842,168	US\$15,842,168	N/A	US\$3,864,318	US\$42.1 million
			Ministry of Health (RWA-H-MOH)	US\$148,528,188	-	US\$148,528,188	US\$148,528,188	N/A	US\$169,818,039	US\$643.4 million
20	Solomon Islands	Malaria	Ministry of Health and Medical Services (SLB-M-MHMS)	US\$5,579,078	US\$3,986,812	US\$1,592,266	US\$1,592,266	N/A	N/A	US\$4,857,000

N	Country	Disease Component	Proposed Principal Recipient (Grant name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
21	Solomon Islands	TB	Ministry of Health and Medical Services (SLB-T-MHMS)	US\$2,758,339	US\$2,052,679	US\$705,660	US\$705,660	N/A	N/A	US\$1,293,501
22	Sudan	HIV	United Nations Development Programme (SDN-H-UNDP)	US\$20,870,921	US\$3,902,774	US\$16,968,147	US\$16,968,147	N/A	US \$26,787,657	US \$8.3 million
23	Swaziland	TB	National Emergency Response Council on HIV and AIDS (SWZ-T-NERCHA)	US\$21,189,356	US\$12,045,397	US\$9,143,959	US\$9,143,959	N/A	US\$16,692,038	US\$29.8 million
24	Tanzania	TB/HIV	Save the Children (TZA-C-STC)	US\$13,059,126	-	US\$13,059,126	US\$13,059,126	N/A	N/A	HIV: US\$1,814 million TB: US\$160 million

GF/B32/EDPo8 Decision on the Secretariat's Recommendation on Grant Extensions

Approved by the Board on 30 June 2015 by electronic vote.

The Board:

1. Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER05 – Revision 1.

Table 2: Secretariat's Recommendations on Grant Extensions

Country	Grant Name	Period of Extension (Months)	Additional Funding	Rationale
Guatemala	GUA-610-G04-T	9	N/A	To allow for continuation of program activities while concept note is being negotiated.
Haiti	HTI-102-G09-H	6	US\$4,408,872	To allow for continuation of program activities while concept note is being negotiated.
India	IDA-T-CTD	3	US\$28,537,483	To allow for continuation of program activities and initiate the procurement of second-line drugs.
Lao (PDR)	LAO-708-G09-M	6	US\$4,142,469	To allow for continuation of program activities while concept note is being negotiated
Nepal	NEP-H-SCF	12	US\$11,776,804	To allow for continuation of program activities while concept note is being developed and reviewed.
Nepal	NEP-M-SCF	12	US\$3,454,834	
Syria	SYR-607-G01-T	13	N/A	To ensure the continuation of life-saving services while the concept note is being developed.
Zanzibar	ZAN-T-MOHSW	3	N/A	To allow for continuation of program activities while concept note is being negotiated

GF/B32/EDP09 Terms of Reference of the Ethics Officer

Decision not approved.

Decision point **GF/B33/EDP09 *Terms of Reference of the Ethics Officer*** was not approved by the Board.

GF/B32/EDP10 Approval of the Report of the Thirty-Third Board Meeting

Approved by the Board on 7 July 2015 by electronic vote.

The Board approves the Report of the Thirty-Third Board Meeting, as set forth in GF/B33/24.

GF/B32/EDP11 Location of the Thirty-Fourth Board Meeting

Approved by the Board on 17 July 2015 by electronic vote.

The Board decides to convene the Thirty-Fourth Board Meeting in Geneva, Switzerland as an exception to article B.6.1 of the Operating Procedures of the Board and Committees.

GF/B32/EDP12 Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation

Approved by the Board on 24 July 2015 by electronic vote.

The Board:

1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ERO7 ("Table 1");
2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;
3. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation

N	Country	Disease Component	Proposed Principal Recipient (Grant Name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
1	Afghanistan	Malaria	UNDP (AFG-M-UNDP)	US\$19,627,543	US\$3,238,475	US\$16,389,068	US\$16,389,068	US\$5,110,657	US\$357,746	N/A
2	Botswana	Malaria	Ministry of Health (BWA-M-BMOH)	US\$5,128,153	US\$0	US\$5,128,153	US\$5,128,153	N/A	N/A	US\$15.2 million
3	Comoros	TB	Association Comorienne pour le Bien-Etre de la Famille (COM-T-ASCOBEF)	€1,817,850	€0	€1,817,850	€1,817,850	N/A	N/A	€280,625
4	Congo (Democratic Republic)	TB/HIV	Stichting Cordaid (COD-H-CORDAID)	US\$72,046,946	US\$12,172,170	US\$59,874,776	US\$178,696,981	US\$14,495,000	US\$0	HIV: US\$20 million TB: US\$9 million
			SANRU Rural Health Program (COD-H-SANRU)	US\$75,453,105	US\$21,902,099	US\$53,551,006				
			Ministry of Health (COD-H-MOH)	US\$22,577,929	US\$0	US\$22,577,929				
			Caritas Internationalis (COD-T-CARITAS)	US\$38,870,165	US\$7,910,464	US\$30,959,701				
			Ministry of Health (COD-H-MCOD-T-MOH)	US\$13,831,917	US\$2,098,348	US\$11,733,569				
5	Somalia	TB	World Vision International (SOM-T-WV)	US\$25,116,723	US\$19,416,723	US\$5,700,000	US\$5,700,000	N/A	N/A	

N	Country	Disease Component	Proposed Principal Recipient (Grant Name)	Total Program Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
					Existing Funding	Recommended Incremental Funding				
6	Swaziland	HIV	Coordinating Assembly of Non-governmental Organisations (CANGO) (SWZ-H-CANGO)	US\$5,636,567	US\$0	US\$5,636,567	US\$35,552,624		US\$16,692,038	US\$157.6 million
			National Emergency Response Council on HIV and AIDS (NERCHA) (SWZ-H-NERCHA)	US\$39,448,898	US\$9,532,841	US\$29,916,058				

GF/B32/EDP13 Decision on the Secretariat's Recommendation on Grant Extensions

Approved by the Board on 24 July 2015 by electronic vote.

The Board:

1. Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER07.

Table 2: Secretariat's Recommendations on Grant Extensions

Country	Grant Name	Period of Extension (Months)	Additional Funding	Rationale
Abidjan-Lagos Corridor Organization	MAW-607-G01-H	6	-	To allow for continuation of programmatic activities while the regional concept note is being discussed.
Djibouti	DJB-613-G05-H	7	-	To allow for continuation of programmatic activities while the concept note is being developed and discussed.
Guinea-Bissau	GNB-M-UNDP	9	€1,230,107	To allow for continuation of programmatic activities while the concept note is being discussed.
Kosovo	KOS-711-G04-H	12	€1,105,095	To allow for continuation of programmatic activities while the revised concept note is being developed and discussed.
Nigeria	NGA-T-IHVN	6	US\$18,866,347	To allow for continuation of programmatic activities while the concept note is being discussed.
Pakistan	PKS-M-DOMC	12	US\$15,648,873	To allow for continuation of programmatic activities while Framework Agreement is being negotiated.
Pakistan	PKS-T-NTP	12	US\$5,360,405	

GF/B32/EDP14 Terms of Reference of the Ethics Officer

Approved by the Board on 30 July 2015 by electronic vote.

1. Based on the recommendation of the Board Leadership, the Board:
 - a. Approves the Terms of Reference of the Ethics Officer, as set forth in Annex 1 to document GF/B33/ER08; and
 - b. Notes that the Terms of Reference of the Ethics Officer supersede the Board's earlier decisions regarding the reporting arrangement for the Ethics Officer (GF/B33/DP09)
2. Accordingly, the Board instructs the Secretariat to launch the recruitment process for the Ethics Officer, who will be jointly selected by the Audit and Ethics Committee (AEC) and the Executive Director, and appointed by the Board on a no-objection basis for a three-year term that may be renewed no more than once.
3. The Board requests the AEC and Finance and Operational Performance Committee to determine the future budgetary implications of this function as part of the standard Operating Expenses budget approval process, with particular consideration given to methods for maximizing value for money.

GF/B32/EDP15 Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation

Approved by the Board on 11 September 2015 by electronic vote.

The Board:

1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B33/ER09 (“Table 1”);
2. Approves the reinvestment of newly identified existing funds for the Burkina Faso TB/HIV grant (BFA-H-SPCNLS) and its resultant total program budget, as listed in Table 2 of Section IV to GF/B33/ER09;
3. Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
4. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
5. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation

Applicant	Disease Component	Grant Name	Currency	Total Program Budget	Existing funding	Recommended Incremental Funding	Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitments
Belize	TB/HIV	BLZ-C-UNDP	US\$	3,451,271	179,901	3,271,370	3,271,370	0	430,707	HIV: 7.3 million TB:1.2 million
Burkina Faso	HSS	BFA-S-PADS	€	17,347,022	0	17,347,022	17,347,022	0	0	-
Burkina Faso	Malaria	BFA-M-PADS	€	59,286,922	5,908,195	53,378,727	53,378,727	N/A	0	39.3 million
Cambodia	HIV/AIDS	KHM-H-NCHADS	US\$	36,130,185	35,438,394	691,791	691,791	0	0	21.8 million
Cambodia	HSS	KHM-S-PRMOH	US\$	12,581,260	4,781,261	7,799,999	7,799,999	0	0	547 million
Center for Health and Policy Studies	TB	QMZ-T-PAS	US\$	6,051,191	0	6,051,191	6,051,191	N/A	0	N/A
Elimination 8 - SADC	Malaria	QPA-M-E8S	US\$	17,817,031	0	17,817,031	17,817,031	N/A	2,272,514	N/A
Guinea	HIV	GIN-H-CNLS	US\$	48,652,556	9,945,408	38,707,148	49,203,445	23,500,000	13,700,000	19.9 million
		GIN-H-PSI	US\$	14,071,558	3,575,261	10,496,297				
India	Malaria	IDA-M-NVBDCP	US\$	107,452,367	46,390,090	61,062,277	66,895,696	0	98,854,539	269 million
		IDA-M-CARITAS	US\$	8,982,983	3,149,564	5,833,419				
India	TB/HIV	IDA-H-NACO	US\$	240,455,638	50,968,995	189,486,644	422,564,604	55,498,692	136,632,227	1,195 million (HIV) 867 million (TB)
		IDA-H-IHAA	US\$	21,790,613	14,765,221	7,025,392				
		IDA-H-PLAN	US\$	8,019,727	0	8,019,727				
		IDA-H-SAATHII	US\$	4,579,042	0	4,579,042				
		IDA-T-CTD	US\$	235,295,495	39,374,081	195,921,415				
		IDA-T-IUATLD	US\$	24,843,657	12,993,349	11,850,308				

Italic text: Date corrected via GF/B33/ER18 Table 5

Applicant	Disease Component	Grant Name	Currency	Total Program Budget	Existing funding	Recommended Incremental Funding	Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitments
Belize	TB/HIV	BLZ-C-UNDP	US\$	3,451,271	179,901	3,271,370	3,271,370	0	430,707	HIV: 7.3 million TB:1.2 million
Burkina Faso	HSS	BFA-S-PADS	€	17,347,022	0	17,347,022	17,347,022	0	0	-
Burkina Faso	Malaria	BFA-M-PADS	€	59,286,922	5,908,195	53,378,727	53,378,727	N/A	0	39.3 million
Cambodia	HIV/AIDS	KHM-H-NCHADS	US\$	36,130,185	35,438,394	691,791	691,791	0	0	21.8 million
Cambodia	HSS	KHM-S-PRMOH	US\$	12,581,260	4,781,261	7,799,999	7,799,999	0	0	547 million
Center for Health and Policy Studies	TB	QMZ-T-PAS	US\$	6,051,191	0	6,051,191	6,051,191	N/A	0	N/A
Elimination 8 - SADC	Malaria	QPA-M-E8S	US\$	17,817,031	0	17,817,031	17,817,031	N/A	2,272,514	N/A
Guinea	HIV	GIN-H-CNLS	US\$	48,652,556	9,945,408	38,707,148	49,203,445	23,500,000	13,700,000	19.9 million
		GIN-H-PSI	US\$	14,071,558	3,575,261	10,496,297				
		IDA-T-WV	US\$	6,904,828	1,222,752	5,682,076				
Kenya AIDS NGOs Consortium Regional	HIV	QPB-H-KANCO	US\$	5,566,264	0	5,566,264	5,566,264	N/A	232,663	N/A
Kenya	Malaria	KEN-M-TNT	US\$	68,437,630	49,352,995	19,084,635	23,485,108	0	0	10.2 million
		KEN-M-AMREF	US\$	8,836,261	4,435,788	4,400,473				
Kenya	TB/HIV	KEN-H-KRCS	US\$	38,522,849	20,611,090	17,911,759	101,857,426	34,279,159	96,010,045	HIV: 510 million TB: 45 million
		KEN-H-TNT	US\$	259,463,768	224,735,660	34,728,108				
		KEN-T-AMREF	US\$	22,645,475	3,769,314	18,876,161				
		KEN-T-TNT	US\$	47,144,474	16,803,076	30,341,398				

Applicant	Disease Component	Grant Name	Currency	Total Program Budget	Existing funding	Recommended Incremental Funding	Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitments
Belize	TB/HIV	BLZ-C-UNDP	US\$	3,451,271	179,901	3,271,370	3,271,370	0	430,707	HIV: 7.3 million TB:1.2 million
Burkina Faso	HSS	BFA-S-PADS	€	17,347,022	0	17,347,022	17,347,022	0	0	-
Burkina Faso	Malaria	BFA-M-PADS	€	59,286,922	5,908,195	53,378,727	53,378,727	N/A	0	39.3 million
Cambodia	HIV/AIDS	KHM-H-NCHADS	US\$	36,130,185	35,438,394	691,791	691,791	0	0	21.8 million
Cambodia	HSS	KHM-S-PRMOH	US\$	12,581,260	4,781,261	7,799,999	7,799,999	0	0	547 million
Center for Health and Policy Studies	TB	QMZ-T-PAS	US\$	6,051,191	0	6,051,191	6,051,191	N/A	0	N/A
Elimination 8 - SADC	Malaria	QPA-M-E8S	US\$	17,817,031	0	17,817,031	17,817,031	N/A	2,272,514	N/A
Guinea	HIV	GIN-H-CNLS	US\$	48,652,556	9,945,408	38,707,148	49,203,445	23,500,000	13,700,000	19.9 million
		GIN-H-PSI	US\$	14,071,558	3,575,261	10,496,297				
Korea (Democratic People's Republic)	TB	PRK-T-UNICEF	US\$	28,796,977	2,566,644	26,230,333	26,230,333	0	0	17.5 million
Lao (People's Democratic Republic)	Malaria	LAO-M-GFMOH	US\$	10,097,655	4,322,986	5,774,669	5,774,669	394,543	489,285	5.6 million
South Sudan	HIV/AIDS	SSD-H-UNDP	US\$	42,464,597	2,267,698	40,196,899	40,196,899	5,600,619	14,270,663	7.25 million
Sri Lanka	TB	LKA-T-MOH	US\$	8,431,195	423,492	8,007,703	8,007,703	-	0	26.5 million
Sudan	HSS	SDN-S-FMOH	US\$	20,445,855	0	20,445,855	20,445,855	0	11,535,447	13.1 million
Suriname	TB/HIV	SUR-C-MOH	US\$	4,045,495	239,572	3,805,923	3,805,923	-	704,980	10.5 million
Tajikistan	HIV/AIDS	TJK-H-UNDP	US\$	17,149,075	111,767	17,037,308	17,037,308	-	0	15.1 million

Applicant	Disease Component	Grant Name	Currency	Total Program Budget	Existing funding	Recommended Incremental Funding	Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitments
Belize	TB/HIV	BLZ-C-UNDP	US\$	3,451,271	179,901	3,271,370	3,271,370	0	430,707	HIV: 7.3 million TB:1.2 million
Burkina Faso	HSS	BFA-S-PADS	€	17,347,022	0	17,347,022	17,347,022	0	0	-
Burkina Faso	Malaria	BFA-M-PADS	€	59,286,922	5,908,195	53,378,727	53,378,727	N/A	0	39.3 million
Cambodia	HIV/AIDS	KHM-H-NCHADS	US\$	36,130,185	35,438,394	691,791	691,791	0	0	21.8 million
Cambodia	HSS	KHM-S-PRMOH	US\$	12,581,260	4,781,261	7,799,999	7,799,999	0	0	547 million
Center for Health and Policy Studies	TB	QMZ-T-PAS	US\$	6,051,191	0	6,051,191	6,051,191	N/A	0	N/A
Elimination 8 - SADC	Malaria	QPA-M-E8S	US\$	17,817,031	0	17,817,031	17,817,031	N/A	2,272,514	N/A
Guinea	HIV	GIN-H-CNLS	US\$	48,652,556	9,945,408	38,707,148	49,203,445	23,500,000	13,700,000	19.9 million
		GIN-H-PSI	US\$	14,071,558	3,575,261	10,496,297				
Togo	TB/HIV	TGO-H-PMT	€	32,779,268	12,880,785	19,898,483	23,758,535	US\$3,178,346	14,926	10.7 million
		TGO-T-PMT	€	4,118,558	258,505	3,860,053				
Zanzibar	Malaria	QNB-M-MOH	US\$	5,666,833	2,988,238	2,678,595	2,678,595	353,964	4,086,318	1.38 million

GF/B32/EDP16 Decision on the Secretariat's Recommendation on Grant Extensions

Approved by the Board on 11 September 2015 by electronic vote.

The Board:

1. Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B33/ER09

Table 3: Secretariat's Recommendation on Grant Extensions

	Country	Disease Component	Grant Name	Period of Extension (Months)	Currency	Additional Funding	Rationale
1	Liberia	TB	LBR-T-MOH	9	US\$	-	To allow the applicant to focus on prioritized and feasible program activities following the Ebola emergency period. The grant has previously been extended by 12 months and therefore additional extensions require Board approval.
2	Madagascar	HIV	MDG-809-G11-H	9	US\$	-	To allow for continuation of program activities while a revised concept note is being developed and discussed and subsequent steps are completed.
3	Madagascar	HIV	MDG-809-G12-H	9	US\$	3,106,166	
4	Syria	HIV	SYR-011-G02-H	11	US\$	103,589	To allow for continuation of program activities while the modality in accessing funding in the challenging operating environment is being developed and subsequent steps finalized. The grant had previously been extended by 12 months due to challenging security situation and therefore the current request for extension requires Board approval.

GF/B32/EDP17 Strategy Development Process – Alignment of Strategy Cycle

Decision not approved.

Decision GF/B32/EDP17: Strategy Development Process – Alignment of Strategy Cycle was not approved by the Board.

GF/B32/EDP18 Approval of the Governance Performance Assessment Framework

Approved by the Board on 21 September 2015 by electronic vote.

1. Based on the recommendation of the Transitional Governance Committee, the Board approves the Governance Performance Assessment Framework, as set forth in Annex 1 to GF/B33/ER11 (the “Framework”).
- 2 The Board agrees with the approach for partially implementing the Framework in 2015, as described in GF/B33/ER11, and acknowledges that full implementation of the Framework will start in 2016

GF/B32/EDP19 Appointment of Member of the Finance and Operational Performance Committee

Approved by the Board on 8 October 2015 by electronic vote.

The Board approves the appointment of Eiji Hinoshita as a voting member of the Finance and Operational Performance Committee for a term that will expire on 1 May 2016, or until the appointment of his successor.

GF/B32/EDP20 Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation

Approved by the Board on 12 October 2015 by electronic vote.

The Board:

1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B33/ER14 ("Table 1");
2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation

	Applicant	Component	Grant Name	Grant End Date	Currency	Total Program Budget	Existing Funding	Incremental Amount for Board Approval	Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
1	Azerbaijan	TB	AZE-T-MOH	30 June 2018	US\$	10,976,139	4,613,354	6,362,785	6,362,785	-	0	53 million
2	Bangladesh	HIV/AIDS	BGD-H-NASP	30 November 2017	US\$	14,287,612	0	680,213	10,249,603	-	2,321,421	24.1 million
			BGD-H-SC	30 November 2017	US\$		1,905,639	5,896,316				
			BGD-H-ICDDR	30 November 2017	US\$		2,132,370	3,673,074				
3	Cape Verde	TB/HIV	CPV-C-CCSSIDA	31 December 2017	€	2,353,542	213,186	2,140,357	2,140,357	-	220,270	3.8 million
4	Comoros	Malaria	COM-M-PNLP	31 December 2018	€	6,353,107	1,656,155	4,696,952	4,696,952	384,037	0	1 million
5	Haiti	HIV/AIDS	HTI-C-PSI	31 December 2017	US\$	45,055,551	1,907,173	43,148,378	43,148,378	-	0	49 million
6	Lao (People's Democratic Republic)	HIV/AIDS	LAO-H-GFMOH	31 December 2017	US\$	8,374,163	2,073,717	6,300,446	6,300,446	1,297,436	812,789	4.6 million
7	Panama	TB/HIV	PAN-C-UNDP	31 December 2018	US\$	7,174,723	1,294,770	5,879,953	5,879,953	-	0	92.6 million
8	Sri Lanka	Malaria	LKA-M-MOH	31 December 2018	US\$	7,406,075	3,747,266	3,658,809	3,658,809	-	0	17.8 million

9	Zanzibar	TB/HIV	QNB-C-MOH	31 December 2017	US\$	10,224,371	1,105,518	9,118,853	9,118,853	728,547	270,108	2.76 million
---	----------	--------	-----------	------------------	------	------------	-----------	-----------	-----------	---------	---------	--------------

Regional grants

	Applicant	Component	Grant Name	Grant End Date	Currency	Total Program Budget	Existing Funding	Incremental Amount for Board Approval	Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
1	Abidjan-Lagos Corridor Organization (OCAL)	HIV/AIDS	QPF-H-ALCO	<i>31 December 2018²</i>	€	8,476,296	7,860,677	615,619	615,619	-	540,881	-
2	African Network for the Care of Children Affected by HIV/AIDS (ANECCA)	HIV/AIDS	QPA-H-ANECCA	<i>30 November 2018³</i>	US\$	3,666,845	0	3,666,845	3,666,845	-	0	-
3	ECSA-HC Uganda Supranational National Reference Laboratory	TB	QPA-T-ECSA	31 October 2019	US\$	6,136,774	0	6,136,774	6,136,774	-	0	-
4	Humanist Institute for Cooperation with Developing Countries, Southern Africa (HIVOS)	HIV/AIDS	QPA-H-HIVOS	31 December 2018	US\$	11,465,336	0	11,465,336	11,465,336	-	2,670,950	-
5	Removal of Legal Barriers (RLB)	HIV/AIDS	QPA-H-UNDP	<i>31 December 2018</i>	US\$	10,522,144	0	10,522,144	10,522,144	-	0	-

Italics: Date corrected via GF/B33/ER18 Table 5.

GF/B32/EDP21 Decision on the Secretariat's Recommendation on Grant Extensions

Approved by the Board on 12 October 2015 by electronic vote.

The Board:

1. Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B33/ER14.

Table 2: Secretariat's Recommendation on Grant Extensions

Country	Disease Component	Grant Name	Currency	Period of Extension (Months)	Additional Funding	Rationale
Angola	Malaria	AGO-M-MOH	US\$	12	0	To prevent the disruption of services and stock-out of ACTs.
Sri Lanka	TB	SRL-607-G07-T	US\$	3	379,615	To allow for continuation of grant activities while the review and signing of the Framework Agreement is being processed by the country.
Sri Lanka	Malaria	SRL-809-G10-M	US\$	3	N/A	

GF/B32/EDP22 Decision on the Secretariat's Recommendation on waiver of the Board condition for Congo HIV grant

Approved by the Board on 12 October 2015 by electronic vote.

The Board:

1. Approves waiver of the Board condition imposed in the Congo HIV grant (COG-911-G06-H) restricting the “use of funds to finance activities other than (i) the procurement of Health Products and Pharmaceuticals and (ii) other activities deemed essential in the framework of the program,” and
2. Approves disbursement of grant funds to the principal recipient the Secretariat Executif Permanent/Comité National de Lutte contre le SIDA (SEP /CNLS) to conduct activities essential to the implementation of the HIV program.

GF/B32/EDP23 Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation

Approved by the Board on 19 October 2015 by electronic vote.

The Board:

1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV of GF/B33/ER15 ("Table 1");
2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation

N	Applicant	Component	Grant Name	Grant End Date	Currency	Total Program Budget	Existing Funding	Incremental Amount for Board Approval	Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
1	Dominican Republic	HIV/AIDS	DOM-H-CONAVIH	31 December 2018	US\$	20,247,495	6,657,968	3,921,319	13,589,527	N/A	0	82 million
			DOM-H-IDCP	31 December 2018	US\$		0	9,668,208				
2	Lao (People's Democratic Republic)	HSS	LAO-S-GFMOH	31 December 2017	US\$	3,700,000	0	3,700,000	3,700,000	N/A	0	1.1 million
3	Malawi	Malaria	MWI-M-MOH	31 December 2017	US\$	48,592,107	27,249,926	15,821,021	21,342,181	5,245,911	0	14.1 million
			MWI-M-WVM	31 December 2017	US\$		0	5,521,160				
4	Malawi	TB/HIV	MWI-C-MOH	31 December 2017	US\$	388,824,633	106,710,993	282,113,640	282,113,640	37,213,777	69,869,573	48.4 million

GF/B32/EDP24 Decision on the Secretariat's Recommendation on Grant Extensions

Approved by the Board on 19 October 2015 by electronic vote.

The Board:

1. Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B33/ER15.

Table 2: Secretariat's Recommendation on Grant Extensions

Country	Disease Component	Grant Name	Currency	Period of Extension (Months)	Additional Funding	Rationale
Kyrgyzstan	HIV	KGZ-H-UNDP	US\$	6	3,458,071	To allow for continuation of grant activities while the concept note is being reviewed and subsequent steps completed.

GF/B32/EDP25 Appointment of Member of the Strategy, Investment and Impact Committee

Approved by the Board on 29 October 2015 by electronic vote.

The Board approves the appointment of Dr Suriya Wongkongkathep as a voting member of the Strategy, Investment and Impact Committee for the remainder of his predecessor's two-year term, or until the appointment of his successor.

GF/B32/EDP26 Global Fund Strategy Cycle

Approved by the Board on 10 November 2015 by electronic vote.

1. Based on the recommendations of the Strategy, Investment and Impact Committee (the “SIIC”), as set forth in GF/B33/ER17, the Board decides the next strategy should cover the six-year period that begins on 1 January 2017 and ends on 31 December 2022 (the “2017 – 2022 Strategy”), with a mid-point review of progress and implementation.
2. The Board notes the importance of coherence between the strategy, allocation and replenishment, as well as the need to provide advanced articulation of the Global Fund’s strategy and objectives to guide implementation planning, facilitate advocacy efforts and support mobilization of resources.
3. Accordingly, the Board directs the SIIC, or its successor committee, to develop a timeline for developing and finalizing the strategy that will commence immediately after the 2017 – 2022 Strategy as part of the mid-point review of the 2017 – 2022 Strategy.

GF/B32/EDP27 Decision on the Secretariat's Recommendation on Additional Funding from the 2014 Allocation

Approved by the Board on 13 November 2015 by electronic vote.

The Board:

1. Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B33/ER18 (collectively, "Table 1");
2. Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Approves the additional funding for the Zimbabwe HIV Program and its resultant total program budget, as listed in Table 1c of Section IV to GF/B33/ER18;
4. Approves the reinvestment of within-allocation efficiencies for the Bangladesh malaria and Cote d'Ivoire malaria grants and their resultant total program budget, as listed in Table 2 of Section IV to GF/B33/ER18;
5. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1a: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation (Countries)

N	Country	Disease component	Grant name	Grant end date	Currency	Total program budget	Existing funding	Incremental amount for Board approval	Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic commitment
1	Armenia	HIV/AIDS	ARM-MOH-H	30 Sept 2018	US\$	5,626,288	710,948	3,240,258	4,915,340	N/A	5,015,040	6.2 million
			ARM-MEA-H	30 Sept 2018	US\$		0	1,675,082				
2	Azerbaijan	HIV/AIDS	AZE-H-MOH	30 June 2018	US\$	9,887,685	3,604,730	6,282,955	6,282,955	N/A	0	23.6 million
3	Belarus	HIV/AIDS	BLR-H-RSPCMT	31 Dec 2018	US\$	13,727,239	1,744,481	11,982,758	11,982,758	N/A	191,393	51.8 million
4	Belarus	TB	BLR-T-RSPCMT	31 Dec 2018	US\$	12,325,452	452,141	11,873,311	11,873,311	N/A	0	189.9 million
5	Benin	HIV/AIDS	BEN-H-BENPNLS	31 Dec 2017	€	28,641,072	21,500,531	0	4,860,581	N/A	0	7.23 million
			BEN-H-PlanBen	31 Dec 2017	€		2,279,960	4,860,581				
6	Benin	Malaria	BEN-M-PNLP	31 Dec 2017	€	31,541,017	7,904,770	23,636,247	23,636,247	8,372,774	0	6.72 million
7	Benin	TB	BEN-T-PNTUB	31 Dec 2017	€	5,988,747	1,369,346	4,619,401	4,619,401	398,982	0	1.36 million
8	Côte d'Ivoire*	Malaria	CIV-M-SCI	30 Dec 2017	€	12,999,177	8,899,472	4,099,706	4,099,706	N/A	19,532,595	65,916,636
9	Dominican Republic	TB	DOM-T-MSPAS	31 Dec 2018	US\$	8,373,610	608,585	7,765,025	7,765,025	N/A	0	67.1 million
10	El Salvador	TB	SLV-T-MOH	31 Dec 2018	US\$	9,950,916	150,000	9,800,916	9,800,916	N/A	0	24,456,238
11	Gabon	TB	GAB-T-MSPS	31 Dec 2018	€	3,630,386	0	3,630,386	3,630,386	N/A	0	10.5 million
12	Gambia	TB	GMB-T-NLTP	31 Dec 2017	US\$	7,989,687	1,343,987	6,645,700	6,645,700	352,000	0	356,990
13	Jamaica	HIV/AIDS	JAM-H-MOH	31 Dec 2018	US\$	15,242,178	323,560	14,918,618	14,918,618	N/A	0	53.6 million
14	Paraguay	TB	PRY-T-AVA	31 Dec 2018	US\$	5,988,073	425,056	5,563,017	5,563,017	N/A	0	15.7 million

15	Tajikistan	TB	TJK-T-HOPE	31 Dec 2017	US\$	17,966,668	4,677,082	8,622,891	13,289,586	N/A	0	16,006,534
			TJK-T-RCTC	31 Dec 2017	US\$		0	4,666,695				
16	Timor-Leste	TB	TLS-708-Go4-T	31 Dec 2017	US\$	4,813,831	625,139	4,188,692	4,188,692	N/A	908,297	10.95 million
17	Timor-Leste	HIV/AIDS	TLS-H-MOH	31 Dec 2017	US\$	4,312,116	3,944,635	367,480	367,480	N/A	0	4,426,110
18	Viet Nam	Malaria	VNM-M-NIMPE	31 Dec 2017	US\$	15,249,222	2,769,522	12,479,700	12,479,700	4,797,180	13,547,023	12.7 million

Table 1b: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation (Regional Applicant)

N	Applicant	Disease Component	Currency	Grant name	Grant end date	Recommended budget	Total program budget	Existing funding	Incremental amount for Board approval	Recommended total incremental funding	Unfunded Quality Demand
1	ICW Latina	HIV/AIDS	US\$	QRA-H-HIVOS	31 Dec 2018	4,330,296	4,330,296	0	4,330,296	4,330,296	0

Table 1c: Secretariat's Funding Recommendation on Additional Funding for Zimbabwe HIV Program

Applicant	Grant Name	Currency	Approved Grant Budget	Revised Budget for Board Approval	Source of Funding	Incremental Funding Already Approved	Additional Incremental Funding for Board Approval	Revised Unfunded Quality Demand
Zimbabwe	ZIM-H-UNDP	US\$	437,272,910	468,705,052	Incentive funding	126,053,783	25,274,085	127,621,036
					CIFF		6,160,057	

Table 2: Reinvestment of Within-Allocation Efficiencies for Previously-Approved Programs

Applicant	Grant Name	Currency	Approved Grant Budget	Revised Budget for Board Approval	Existing Funding	Revised Existing Funding	Incremental Funding Already Approved	Additional Incremental Funding for Board Approval	Revised Unfunded Quality Demand
Bangladesh ⁴	BGD-M-BRAC	US\$	9,607,092	9,800,254	113,476	228,972	9,493,616	77,666	17,213,518
	BGD-M-NMCP	US\$	15,744,966	15,883,897	3,415,293	3,471,219	12,329,673	83,005	
Côte d'Ivoire	CIV-M-MOH	€	77,924,323	82,496,017	20,231,712	24,056,646	57,692,611	746,760	19,532,595

⁴ The GAC recommends that the Board approve an increase to the budget amount of the Bangladesh malaria grants BAN-M-NMCP and BAN-M-BRAC. The additional amount requested is within the allocation and represents reinvestment of undisbursed and unused cash funds from round 10 grants that were not included in the total budget when the Board approved an incremental amount for the Bangladesh malaria grants on 30 June 2015 (GF/B33/EDP05). The CCM requests to reinvest this amount in unfunded quality demand, in line with the current program and TRP recommendations.

GF/B32/EDP28 Decision on the Secretariat's Recommendation on Grant Extensions

Approved by the Board on 13 November 2015 by electronic vote.

The Board:

1. Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B33/ER18.

Table 3: Secretariat's Recommendation on Grant Extensions

Country	Disease Component	Grant Name	Currency	Period of Extension (Months)	Additional Funding	Rationale
Uzbekistan	HIV/AIDS	UZB-H-UNDP	US\$	6	1,562,783	To allow for continuation of grant activities while the concept note is being reviewed and subsequent steps completed.

GF/B32/EDP29 Decision on the Secretariat’s Recommendation on Policy Exceptions for Processing HIV and TB Funding Applications from Certain Countries in the Middle East Region

Approved by the Board on 13 November 2015 by electronic vote.

The Board:

1. Acknowledges the current political context and challenging implementation environment in Iraq, Palestine, Syria and Yemen due to ongoing conflicts; and
2. Accordingly, approves the following policy exceptions for processing HIV and TB funding applications from these countries to access relevant 2014-2016 funding allocations:
 - Waiver of the CCM eligibility requirements;
 - Waiver of the counterpart financing requirement; and
 - Waiver of the “willingness-to-pay” requirement

GF/B32/EDP30 Appointment of Member of the Strategy, Investment and Impact Committee

Approved by the Board on 12 November 2015 by electronic vote.

The Board approves the appointment of Ambassador Lennarth Hjelmaker as a voting member of the Strategy, Investment and Impact Committee for the remainder of his predecessor's two-year term, or until the appointment of his successor.